ERBB2 and neoplasm: CXCL9, a chemokine involved in modulating immune responses by promoting tumor-infiltrating lymphocytes (TILs), has been associated with a favorable prognosis in ER-negative/HER2-negative breast cancer, correlating with improved survival and higher TIL levels [16, 17].